Humanized Antibody To Attack Resistant Multiple Myeloma Cells in Bone Marrow

MedicalResearch.com Interview with:

Hans van Eenennaam, Ph.D. Executive vice president antibody research and site head Aduro Biotech Europe

Dr. van Eenennaam

Hans van Eenennaam, Ph.D.
Executive vice president antibody research and site head
Aduro Biotech Europe

MedicalResearch.com: What is the background for this study?

Response: A PRoliferation Inducing Ligand (APRIL) is a member of the tumor necrosis factor superfamily and has been shown to stimulate the proliferation and survival of healthy B-lymphocytes. Malignant B-lymphocytes, such as multiple myeloma, use APRIL primarily in the bone marrow to support its proliferation and survival. Studies have shown that APRIL is overproduced in patients with multiple myeloma and mediates primarily via binding to B-cell maturation antigen (BCMA) to stimulate a wide variety of responses that promote multiple myeloma growth and survival, as well as suppressing the immune system so that the tumor cells are protected and sustained in the bone marrow and can escape current available treatments.

Continue reading